GNT-PHARMA
GNT Pharma has successfully completed a Phase III clinical trial for crisdesalazine , a new drug for treating canine cognitive dysfunction syndrome or Alzheimer’s disease.
In the clinical study conducted with 48 companion dogs with severe cognitive dysfunction at 7 veterinary hospitals including Seoul National University Animal Hospital, crisdesalazine-treated group demonstrated outstanding and significant efficacy compared to the placebo group in canine cognitive dysfunction rating scale, the primary outcome measure, as well as in canine dementia scale, the secondary outcome measure. Efficacy was identified both at the 4-week and 8-week treatment in companion dogs that received 5 mg/kg or 10 mg/kg of crisdesalazine. No adverse events were found in relation with the administration of crisdesalazine.
Davis research group at the University of California reported that 28% of companion dogs aged 11~12 and 68% of such dogs aged 15~16 suffer from cognitive dysfunction. As lifespan of companion dogs increases thanks to the advancement in veterinary science and healthcare, their dementia prevalence rate is on the rise. But the increase in companion dogs with dementia is emerging as a serious socio-economic problem due to the unavailability of treatment for dogs with dementia.
Crisdesalazine is a multi-target drug developed to provide strong antioxidant effect and safe anti-inflammatory action to prevent amyloid plaque, neurofibrillary tangle, and neurodegeneration that cause Alzheimer’s disease and companion dog’s dementia. Earlier, scientists at GNT Pharma proved that crisdesalazine reduced amyloid plaques and neuronal death while improving cognitive function in the Alzheimer’s disease mice models.
“Demonstration of safety and outstanding efficacy of crisdesalazine in companion dogs with dementia is a groundbreaking outcome and we recently filed an application for the PCT patent,” said Dr. Jin Hwan Lee, Head of GNT Pharma Animal Healthcare Division.
“We expect to complete its Phase II clinical study in 2~3 years for patients with Alzheimer’s disease,” said Dr. Byoung Joo Gwag, CEO of GNT Pharma and inventor of crisdesalazine. “We plan to submit an application to the Ministry of Food and Drug Safety in the second half year for the clinical study of crisdesalazine for treating Alzheimer’s disease.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20200114005324/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PUMA Partners with Logistics Reply to Accelerate AI-Driven Innovation in Warehousing20.11.2025 11:00:00 CET | Press release
Logistics Reply, the Reply group company specialising in innovative supply chain, has extended its collaboration with global sportswear brand PUMA to further optimise daily logistics operations and enhance user experience through the integration of GaliLEA, an AI-powered assistant built on the LEA Reply™ platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120676732/en/ Thanks to GaliLEA, PUMA has seen significant improvements in their daily use of the LEA Reply WMS, including increased user autonomy with less reliance on external support, faster management through quick data access and assisted ticket creation, real-time operational insights for better decision-making, and streamlined logistics workflows that enhance overall system interaction. Following the successful rollout of the LEA Reply™ Warehouse Management System (WMS) across four key distribution centers in Austria, South Africa, and India between 2022 and
euNetworks Appoints Nick Walden as Chief Revenue Officer20.11.2025 10:00:00 CET | Press release
euNetworks has today announced the appointment of Nick Walden as Chief Revenue Officer, effective 02 December 2025. Nick will be based in London and will drive all facets of euNetworks’ sales and commercial strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120550034/en/ Nick Walden - CRO of euNetworks Nick joins euNetworks following 30+ years in the Telecommunications industry, most recently having led the Global Sales function for Infinera (now Nokia) as Senior Vice President – Worldwide Sales. Prior to this, Nick served as Senior Vice President & Managing Director EMEA at Infinera following over a decade of experience in leadership roles at Ciena. “It’s an incredibly exciting time to be joining euNetworks, building on their strong growth and momentum as a critical bandwidth infrastructure provider across Europe. euNetworks’ relentless customer obsession aligns closely with my passion for delivering value for cust
MVNO Europe calls on the European Commission to enable a true Single Market for mobile connectivity and Internet of Things (IoT) through the Digital Networks Act20.11.2025 09:56:00 CET | Press release
The upcoming legislative proposal for a Digital Networks Act (DNA) marks a defining moment for the European Union to build a true Single Market for electronic communications based on openness, competition and innovation. MVNO Europe believes the upcoming DNA should build on the achievements of the existing EU regulatory framework by strengthening competition among diverse providers. This competition drives innovation and delivers tangible benefits for European consumers and businesses. Ensuring genuine choice for end users is essential to maintain Europe’s global competitiveness. In light of the DNA, MVNO Europe stresses the importance of preserving and reinforcing key aspects of the European Electronic Communications Code (EECC):Maintaining the Significant Market Power (SMP) regime is essential to safeguard competition. MVNO Europe calls for the express ability to apply SMP rules to any markets, including mobile markets, as it is vital to prevent abuse of dominant market positions and
Breker Verification Systems and Frontgrade Gaisler Collaborate on High-Reliability RISC-V Fault Tolerant Processor Core20.11.2025 09:00:00 CET | Press release
Breker Verification Systems, whose portfolio solves challenges across the functional verification process for large, complex semiconductors and Frontgrade™ Technologies, a leading provider of high-reliability electronic solutions for space and national security missions today confirmed its RISC-V functional verification solutions were pivotal for verification of the NOEL-V, one of Frontgrade Gaisler’s fault-tolerant RISC-V processor IP cores. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120600508/en/ “The development of Frontgrade Gaisler’s IP cores is guided by a philosophy that does not tolerate design issues,” notes Jan Andersson, Director of Engineering at Frontgrade Gaisler. “This demands the most robust verification environment, something Breker’s verification solution has contributed to improve, with its broad range of tests and in-depth corner case coverage.” The ultra-high verification coverage afforded by Brek
Yagi & Co., Ltd.: Exhibiting for the first time at ISPO Munich 2025, the world's largest trade fair for sports goods, based in Germany20.11.2025 09:00:00 CET | Press release
We propose textiles and products utilising original materials developed by our Materials Division specifically to address environmental, health, and heat countermeasures, primarily within the sports and outdoor sectors. Yagi & Co., Ltd. (TOKYO:7460) (https://www.yaginet.co.jp/en/index.html) will be exhibiting for the first time at ISPO Munich, held in Munich, Germany, over three days from Sunday 30th November to Tuesday 2nd December this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251119473772/en/ Since ancient times, the lava rock formed beneath Mt. Fuji has been carefully protected from changes in surface temperature and weathering. LAVATECH is made by weaving this high-quality underground lava rock. We have achieved a high far-infrared effect by using a special technology to finely crush the lava rock that lies underground at Mt. Fuji for weaving into fibers. This brand of materials enables the creation of new pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom